Drug intelligence / Profile preview

Mianyi No. 2 granules

Development stage: Unknown
Lead developer: China Academy of Chinese Medical Sciences
Administration: Oral

Overview

Mianyi No. 2 granules is a Traditional Chinese Medicine (TCM) formulation developed to address immune nonresponse in adults with HIV-1 infection undergoing antiretroviral therapy (ART). Clinical trials have demonstrated its efficacy and safety in significantly increasing CD4+ and CD45RA+ T cell counts, thereby promoting immune reconstitution. The study protocol for its clinical evaluation was approved by the China Academy of Traditional Chinese Medicine.

Other names: 免疫2号颗粒Mianyi granules

Targets

CD4 (T lymphocyte surface antigen)

Beyond the preview

Go deeper on Mianyi No. 2 granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mianyi No. 2 granules.

Explore the full profile